According to the company, Isoplex will be used in situations where a patient is losing blood, such as trauma or surgery, and there is a need to increase blood volume while maintaining the body’s natural balance of minerals and salts. The majority of usage is expected to be in operating theatres, A&E and intensive care units.
IS Pharma said that it will now seek to gain regulatory approvals in other European markets based on the UK approval.
Tim Wright, CEO of IS Pharma, said: “The launch today is a further excellent example of our ability to deliver on strategy by identifying an area of significant market need and rapidly developing, registering and commercializing specialist pharmaceutical brands.”